Sign in
AUPH Stock Price, Chart, Stats & News
Aurinia Pharmaceuticals Inc.
Save
Aurinia Pharmaceuticals Inc. (AUPH) does not currently pay a dividend.
2.03B
Market cap
17.53x
Current P/E
18.21x
Forward P/E
AUPH chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 88.46% |
Operating margin | 37.06% |
Pretax margin | 40.33% |
Net margin | 101.47% |
Effective tax rate | -151.59% |
ROA | 38.21% |
ROE | 70.37% |
D/E | 0.13x |
Interest coverage ratio | 12.06x |
AUPH valuation
P/E | 17.53x |
P/S | 6.70x |
P/B | 3.30x |
P/CF | 14.25x |
P/FCF | 14.13x |
P/OCF | 14.25x |
PEG | 0.02x |
EV multiple | 13.37x |
About
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis.
Similar securities
Based on sector and market capitalization
Report issue